Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontuxizumab in chemorefractory metastatic colorectal cancer
NCT01507545Phase 2Terminated
- Sponsor
- Morphotek
- Start
- Mar 2012
- Primary completion
- Oct 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ontuxizumab in metastatic colorectal cancer (mCRC), sponsored by Morphotek. Started Mar 2012; status: terminated.
02
Drugs
ontuxizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01507545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01507545.